ZBTB16 and acute promyelocytic leukemia: Further research in a murine APL model demonstrated that the co-administration of 8-CPT-cAMP (8-chlorophenylthio-adenosine-3′, 5′-cyclic monophosphate) improves the therapeutic effect of ATRA by enhancing cellular differentiation and increasing PLZF-RARA degradation [56].